sildenafil-citrate and Central-Serous-Chorioretinopathy

Topics: Central Serous Chorioretinopathy; Fluorescein Angiography; Humans; Prospective Studies; Retina; Sildenafil Citrate

Topics: Adult; Central Serous Chorioretinopathy; Chronic Disease; Fluorescein Angiography; Follow-Up Studies; Fundus Oculi; Humans; Male; Phosphodiesterase 5 Inhibitors; Prospective Studies; Retinal Pigment Epithelium; Sildenafil Citrate; Tomography, Optical Coherence

Central serous chorioretinopathy occurs primarily in young caucasian men. It is characterized by the development of a serous detachment of the sensory retina with the apparition of a relative central scotomata. An association with phosphodiesterase 5 inhibitors is reported in some articles. We described two cases of central serous chorioretinopathy following the use of tadalafil and sildenafil.. La choriorétinite séreuse centrale est une pathologie touchant principalement les jeunes hommes caucasiens. Elle se caractérise par un décollement séreux rétinien se traduisant le plus souvent par l’apparition d’un scotome central relatif. Une association avec une prise d’inhibiteurs de la phosphodiestérase de type 5 est relatée dans plusieurs articles. Nous rapportons deux cas de choriorétinite séreuse centrale ayant suivi la prise de tadalafil et sildénafil.

Topics: Central Serous Chorioretinopathy; Humans; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Tadalafil; Tomography, Optical Coherence

The possible effects of sildenafil citrate administration at therapeutic dosage on visual acuity, color vision, intraocular pressure, macular thickness, macular volume, and central serous chorioretinopathy in patients with erectile dysfunction were evaluated. The study consisted of 43 male patients diagnosed as having erectile dysfunction according to the first five question version of International Index of Erectile Function (IIEF-5). All patients were given sildenafil citrate 50 mg po 2 to 3 times/week for a month. The patients were evaluated at the first week and at the end of the treatment. The macular thickness and volume assessments with optic coherence tomography did not differ significantly in foveal, parafoveal areas, parafoveal superior hemisphere, parafoveal inferior hemisphere, parafoveal temporal, superior, nasal, and inferior quadrants. Central serous chorioretinopathy was not found in any of the patients.

Topics: Adult; Aged; Central Serous Chorioretinopathy; Erectile Dysfunction; Humans; Male; Middle Aged; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Vasodilator Agents

Topics: Antimetabolites, Antineoplastic; Antitubercular Agents; Cataract; Central Serous Chorioretinopathy; Corneal Opacity; Ethambutol; Glaucoma; Humans; Interferons; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Sildenafil Citrate; Steroids; Stevens-Johnson Syndrome; Sulfones; Tegafur; Vision Disorders

The purpose of this study was to determine if there is an increased risk of central serous chorioretinopathy (CSC) associated with prescription exposure to phosphodiesterase-5 (PDE-5) inhibitors.. A case-control study linking 2 National Veterans Health Administration databases (clinical and pharmacy) for fiscal years 2004 to 2005. The likelihood of past exposure to PDE-5 inhibitors among newly diagnosed patients with CSC, identified through International Classification of Diseases, 9th Edition, Clinical Modification codes, was compared with 2 age-matched control groups after excluding subjects with risk factors for CSC.. Among 577 men, aged 59 years and younger with newly diagnosed CSC during the study year, 111 were prescribed a PDE-5 inhibitor (19.2%). The proportions of age-matched controls prescribed a PDE-5 inhibitor in the 2 groups were 18.5% and 21.5%. The odds ratio of exposure was 1.05 (95% confidence limit: 0.74-1.22) and 0.87 (95% confidence limit: 0.68-1.12).. Patients with CSC had no increase in prescription exposure to PDE-5 inhibitors than did age-matched control subjects. Although the findings in this study do not support an association between CSC and PDE-5 inhibitors, postmarketing surveillance methods for drug-related side effects have acknowledged limitations.

Topics: Adolescent; Adult; Carbolines; Case-Control Studies; Central Serous Chorioretinopathy; Databases, Factual; Drug Prescriptions; Erectile Dysfunction; Humans; Imidazoles; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Product Surveillance, Postmarketing; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; United States; United States Department of Veterans Affairs; Vardenafil Dihydrochloride; Young Adult